A conformationally-locked p-hydroxybenzylidene imidazolinone derivative for detecting Aβ₄₂ aggregation

Area of Science:

• Neurodegenerative disease research
• Biochemical assay development
• Fluorescent probe technology

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder with no cure, characterized by amyloid-beta (Aβ) protein aggregation.
• Amyloid-beta 42 (Aβ42) species are considered more neurotoxic and central to AD pathophysiology than Aβ40.
• Accurate detection of Aβ42 aggregation is crucial for understanding AD progression and developing therapeutic strategies.

Purpose of the Study:

• To develop a selective and specific fluorescent probe for detecting amyloid-beta 42 (Aβ42) aggregation.
• To characterize the fluorescent properties and selectivity of the novel probe BDI.
• To evaluate the probe's efficacy in detecting Aβ42 aggregation in Alzheimer's disease mouse models.

Main Methods:

• Synthesis and characterization of a conformationally-locked p-hydroxybenzylidene imidazolinone derivative (BDI).
• Assessment of BDI's fluorescence enhancement, selectivity, and specificity towards Aβ42 aggregation.
• Fluorescent co-localization studies in brain tissues from AD transgenic mouse models.

Main Results:

• The developed probe BDI exhibits high selectivity and specificity for Aβ42 aggregation over Aβ40.
• BDI shows remarkable fluorescence enhancement with a large Stokes shift (>100 nm).
• Fluorescent imaging confirmed BDI's ability to detect Aβ42 aggregates in AD mouse brain tissues.

Conclusions:

• The novel probe BDI provides a sensitive and specific tool for detecting Aβ42 aggregation.
• BDI facilitates the differentiation of Aβ42 from Aβ40 species in biological samples.
• This probe holds potential for advancing Alzheimer's disease diagnostics and research.